Jacobs & Co. CA Raises Stake in Pfizer Inc. (NYSE:PFE)

Jacobs & Co. CA increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 301,418 shares of the biopharmaceutical company’s stock after purchasing an additional 19,970 shares during the period. Pfizer accounts for 1.3% of Jacobs & Co. CA’s investment portfolio, making the stock its 27th largest position. Jacobs & Co. CA’s holdings in Pfizer were worth $10,920,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Weaver Consulting Group increased its position in shares of Pfizer by 5.1% during the 4th quarter. Weaver Consulting Group now owns 5,791 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 281 shares during the last quarter. Signature Wealth Management Group increased its position in shares of Pfizer by 0.3% during the 4th quarter. Signature Wealth Management Group now owns 85,732 shares of the biopharmaceutical company’s stock valued at $3,156,000 after purchasing an additional 290 shares during the last quarter. D. Scott Neal Inc. increased its position in shares of Pfizer by 1.3% during the 4th quarter. D. Scott Neal Inc. now owns 22,547 shares of the biopharmaceutical company’s stock valued at $830,000 after purchasing an additional 290 shares during the last quarter. Cox Capital Mgt LLC increased its position in shares of Pfizer by 0.5% during the 1st quarter. Cox Capital Mgt LLC now owns 57,935 shares of the biopharmaceutical company’s stock valued at $2,099,000 after purchasing an additional 293 shares during the last quarter. Finally, BDO Wealth Advisors LLC increased its position in shares of Pfizer by 0.5% during the 4th quarter. BDO Wealth Advisors LLC now owns 57,488 shares of the biopharmaceutical company’s stock valued at $2,116,000 after purchasing an additional 295 shares during the last quarter. 67.36% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently commented on PFE shares. TheStreet lowered Pfizer from a “b” rating to a “c+” rating in a research report on Friday, March 5th. The Goldman Sachs Group set a $41.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday. Royal Bank of Canada initiated coverage on Pfizer in a research report on Wednesday. They set a “sector perform” rating and a $42.00 price target on the stock. DZ Bank restated a “buy” rating and set a $41.00 price target on shares of Pfizer in a research report on Wednesday, February 3rd. Finally, Morgan Stanley reduced their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Friday, January 29th. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Pfizer has a consensus rating of “Hold” and an average target price of $38.47.

NYSE PFE traded up $0.13 on Thursday, hitting $36.04. The company’s stock had a trading volume of 226,276 shares, compared to its average volume of 32,556,707. Pfizer Inc. has a 52-week low of $31.61 and a 52-week high of $43.08. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. The company’s 50-day simple moving average is $35.06 and its 200 day simple moving average is $36.58. The firm has a market cap of $201.02 billion, a P/E ratio of 23.17, a PEG ratio of 2.79 and a beta of 0.70.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing the Zacks’ consensus estimate of $0.46 by ($0.04). The firm had revenue of $11.68 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The company’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.55 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.89 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Featured Article: What is an overbought condition?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.